One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

This poster presents follow-up data from the pivotal trial of brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma showing that 75.1% of patients who achieve a CR following this CART, retain it at 15months, a notable finding in the high risk population recruited. Median PFS and OS have not yet been reached. The data update the NEJM publication and demonstrate sustained clinical response. CART cells were detectable in a proportion of patients with late relapse, suggesting a mechanism of immune escape other than lack of CAR-T persistence.